Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.95 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.95 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.95 |
| ▸ | CFTR | P13569 | 2/20 | 0.95 |
| ▸ | GOPC | Q9HD26 | 2/20 | 0.95 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | KCNA5 | P22460 | 6/20 | 0.52 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6476580 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CFTRGOPC | |
| SCHEMBL8414366 | 0.82 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3CFTRGOPC | |
| SCHEMBL14242083 | 0.81 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3CFTRGOPC | |
| SCHEMBL11632827 | 0.81 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3CFTRGOPC | |
| SCHEMBL10674497 | 0.81 | CYP19A1 (1.00) | SLC6A2SLC6A4SLC6A3CFTRGOPC | |
| SCHEMBL29095977 | 0.81 | SLC6A3 (0.75) | SLC6A2SLC6A4SLC6A3CFTRGOPC | |
| SCHEMBL30638829 | 0.81 | SLC6A3 (0.75) | SLC6A2SLC6A4SLC6A3CFTRGOPC | |
| SCHEMBL3889005 | 0.79 | CFTR (0.68) | SLC6A2SLC6A4SLC6A3CFTRGOPC | |
| Ammonia Solution, Strong SCHEMBL5999497 | 0.78 | CFTR (0.61) | SLC6A2SLC6A4SLC6A3CFTRGOPC | |
| Ammonia Solution, Strong SCHEMBL5999715 | 0.78 | SLC6A3 (0.95) | SLC6A2SLC6A4SLC6A3CFTRGOPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058357-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | K AND K BIOSCIENCE, INC. (US) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058357-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | SIGMAR1, GRM1, GRIN2C | SLC6A2 1494/4885SLC6A4 1569/4885SLC6A3 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.